The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Platelet Aggregation

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Platelet Aggregation


Psychiatry related information on Platelet Aggregation


High impact information on Platelet Aggregation


Chemical compound and disease context of Platelet Aggregation


Biological context of Platelet Aggregation


Anatomical context of Platelet Aggregation


Associations of Platelet Aggregation with chemical compounds

  • Moreover, the defective platelet aggregation and thromboxane formation observed in the patients were not corrected by estrogens [27].
  • The lowest concentration of these agents required to produce biphasic platelet aggregation decreased (i.e., aggregability increased) from a mean +/- SEM of 4.7 +/- 0.6 to 3.7 +/- 0.6 microM (P less than 0.01) for ADP and from 3.7 +/- 0.8 to 1.8 +/- 0.5 microM (P less than 0.01) for epinephrine [28].
  • Platelet aggregation was demonstrated when heparin (0.5 U per milliliter) was incubated with the patients' citrated platelet-rich plasma or with normal platelet-rich plasma in the presence of the patients' serum [29].
  • Thus, platelets obtained from diabetic patients possess increased activity of the prostaglandin synthetase system, and this characteristic may be related to the increased platelet aggregation associated with the disease [30].
  • Platelet cholesterol content and platelet aggregation [31].

Gene context of Platelet Aggregation


Analytical, diagnostic and therapeutic context of Platelet Aggregation


  1. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. Holmberg, L., Nilsson, I.M., Borge, L., Gunnarsson, M., Sjörin, E. N. Engl. J. Med. (1983) [Pubmed]
  2. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. Christman, B.W., McPherson, C.D., Newman, J.H., King, G.A., Bernard, G.R., Groves, B.M., Loyd, J.E. N. Engl. J. Med. (1992) [Pubmed]
  3. A discrete sequence in a platelet integrin is involved in ligand recognition. D'Souza, S.E., Ginsberg, M.H., Matsueda, G.R., Plow, E.F. Nature (1991) [Pubmed]
  4. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. DiMinno, G., Coraggio, F., Cerbone, A.M., Capitanio, A.M., Manzo, C., Spina, M., Scarpato, P., Dattoli, G.M., Mattioli, P.L., Mancini, M. J. Clin. Invest. (1986) [Pubmed]
  5. Effects of moderate alcohol consumption on platelet function, tissue-type plasminogen activator and plasminogen activator inhibitor. Veenstra, J., Kluft, C., Ockhuizen, T.H., vd Pol, H., Wedel, M., Schaafsma, G. Thromb. Haemost. (1990) [Pubmed]
  6. Functional expression of the amplification reaction between serotonin and epinephrine on platelets. De Clerck, F., Xhonneux, B., de Chaffoy de Courcelles, D. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  7. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Li, Z., Xi, X., Gu, M., Feil, R., Ye, R.D., Eigenthaler, M., Hofmann, F., Du, X. Cell (2003) [Pubmed]
  8. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B., Vyas, S.N., FitzGerald, G.A. N. Engl. J. Med. (2001) [Pubmed]
  9. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. Lanas, A., Bajador, E., Serrano, P., Fuentes, J., Carreño, S., Guardia, J., Sanz, M., Montoro, M., Sáinz, R. N. Engl. J. Med. (2000) [Pubmed]
  10. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. Weiss, E.J., Bray, P.F., Tayback, M., Schulman, S.P., Kickler, T.S., Becker, L.C., Weiss, J.L., Gerstenblith, G., Goldschmidt-Clermont, P.J. N. Engl. J. Med. (1996) [Pubmed]
  11. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Ghanayem, B.I., Chulada, P.C., Mahler, J.F., Lee, C.A., Goulding, E.H., Kluckman, K.D., Kim, H.S., Smithies, O. Cell (1995) [Pubmed]
  12. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment. Buchanan, M.R., Dejana, E., Gent, M., Mustard, J.F., Hirsch, J. J. Clin. Invest. (1981) [Pubmed]
  13. Platelet aggregation in response to 5-HT in migraine patients taking oral contraceptives. Hanington, E., Jones, R.J., Amess, J.A. Lancet (1982) [Pubmed]
  14. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Chong, B.H., Pitney, W.R., Castaldi, P.A. Lancet (1982) [Pubmed]
  15. Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects. Coller, B.S., Scudder, L.E., Berger, H.J., Iuliucci, J.D. Ann. Intern. Med. (1988) [Pubmed]
  16. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Ma, L., Elliott, S.N., Cirino, G., Buret, A., Ignarro, L.J., Wallace, J.L. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  17. Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. Robertson, R.M., Robertson, D., Roberts, L.J., Maas, R.L., FitzGerald, G.A., Friesinger, G.C., Oates, J.A. N. Engl. J. Med. (1981) [Pubmed]
  18. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Lefer, A.M., Ogletree, M.L., Smith, J.B., Silver, M.J., Nicolaou, K.C., Barnette, W.E., Gasic, G.P. Science (1978) [Pubmed]
  19. Integrin affinity modulation. Hughes, P.E., Pfaff, M. Trends Cell Biol. (1998) [Pubmed]
  20. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. Clancy, R.M., Leszczynska-Piziak, J., Abramson, S.B. J. Clin. Invest. (1992) [Pubmed]
  21. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. Nachman, R.L., Leung, L.L. J. Clin. Invest. (1982) [Pubmed]
  22. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Pearson, J.D., Gordon, J.L. Nature (1979) [Pubmed]
  23. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Hollopeter, G., Jantzen, H.M., Vincent, D., Li, G., England, L., Ramakrishnan, V., Yang, R.B., Nurden, P., Nurden, A., Julius, D., Conley, P.B. Nature (2001) [Pubmed]
  24. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Hawiger, J., Parkinson, S., Timmons, S. Nature (1980) [Pubmed]
  25. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Moncada, S., Gryglewski, R., Bunting, S., Vane, J.R. Nature (1976) [Pubmed]
  26. Platelet aggregation. Adult-onset diabetes mellitus and coronary artery disease. Davis, J.W., Phillips, P.E., Yue, K.T., Lewis, H.D., Hartman, C.R. JAMA (1978) [Pubmed]
  27. Conjugated estrogens for the management of bleeding associated with renal failure. Livio, M., Mannucci, P.M., Viganò, G., Mingardi, G., Lombardi, R., Mecca, G., Remuzzi, G. N. Engl. J. Med. (1986) [Pubmed]
  28. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. Tofler, G.H., Brezinski, D., Schafer, A.I., Czeisler, C.A., Rutherford, J.D., Willich, S.N., Gleason, R.E., Williams, G.H., Muller, J.E. N. Engl. J. Med. (1987) [Pubmed]
  29. Heparin-induced immune thrombocytopenia. Babcock, R.B., Dumper, C.W., Scharfman, W.B. N. Engl. J. Med. (1976) [Pubmed]
  30. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. Halushka, P.V., Lurie, D., Colwell, J.A. N. Engl. J. Med. (1977) [Pubmed]
  31. Platelet cholesterol content and platelet aggregation. Owen, J.S., Hutton, R.A., McIntyre, N. N. Engl. J. Med. (1980) [Pubmed]
  32. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Angelillo-Scherrer, A., de Frutos, P., Aparicio, C., Melis, E., Savi, P., Lupu, F., Arnout, J., Dewerchin, M., Hoylaerts, M., Herbert, J., Collen, D., Dahlbäck, B., Carmeliet, P. Nat. Med. (2001) [Pubmed]
  33. Thrombospondin promotes cell-substratum adhesion. Tuszynski, G.P., Rothman, V., Murphy, A., Siegler, K., Smith, L., Smith, S., Karczewski, J., Knudsen, K.A. Science (1987) [Pubmed]
  34. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. Woulfe, D., Jiang, H., Morgans, A., Monks, R., Birnbaum, M., Brass, L.F. J. Clin. Invest. (2004) [Pubmed]
  35. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. Fabre, J.E., Nguyen, M., Athirakul, K., Coggins, K., McNeish, J.D., Austin, S., Parise, L.K., FitzGerald, G.A., Coffman, T.M., Koller, B.H. J. Clin. Invest. (2001) [Pubmed]
  36. Antithrombotic activity of TNF-alpha. Cambien, B., Bergmeier, W., Saffaripour, S., Mitchell, H.A., Wagner, D.D. J. Clin. Invest. (2003) [Pubmed]
  37. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. Salvemini, D., Currie, M.G., Mollace, V. J. Clin. Invest. (1996) [Pubmed]
  38. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. Grainick, H.R., Williams, S.B., McKeown, L.P., Rick, M.E., Maisonneuve, P., Jenneau, C., Sultan, Y. J. Clin. Invest. (1985) [Pubmed]
  39. Congenital deficiency of thromboxane and prostacyclin. Pareti, F.I., Mannucci, P.M., D'Angelo, A., Smith, J.B., Sautebin, L., Galli, G. Lancet (1980) [Pubmed]
  40. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Kereiakes, D.J., Runyon, J.P., Kleiman, N.S., Higby, N.A., Anderson, L.C., Hantsbarger, G., McDonald, S., Anders, R.J. Circulation (1996) [Pubmed]
  41. Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Shigeta, O., Gluszko, P., Downing, S.W., Lu, W., Niewiarowski, S., Edmunds, L.H. Circulation (1992) [Pubmed]
WikiGenes - Universities